Balentine LLC’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
– Sell
-11,770
Closed -$1.12M – 307
2024
Q1
$1.12M Buy
11,770
+6,937
+144% +$583K 0.03% 173
2023
Q4
$369K Buy
+4,833
New +$336K 0.01% 349
2023
Q3
– Sell
-4,317
Closed -$407K – 574
2023
Q2
$407K Buy
4,317
+1,173
+37% +$102K 0.01% 313
2023
Q1
$260K Buy
+3,144
New +$247K 0.01% 456
2022
Q4
– Sell
-4,816
Closed -$398K – 660
2022
Q3
$398K Buy
4,816
+1,123
+30% +$108K 0.02% 331
2022
Q2
$351K Sell
3,693
-810
-18% -$83.9K 0.01% 394
2022
Q1
$530K Buy
4,503
+1,986
+79% +$223K 0.02% 282
2021
Q4
$326K Buy
2,517
+461
+22% +$53.8K 0.01% 238
2021
Q3
$233K Buy
+2,056
New +$235K 0.01% 217
2020
Q3
– Sell
-576
Closed -$40K – 388
2020
Q2
$40K Buy
576
+72
+14% +$5.12K ﹤0.01% 274
2020
Q1
$32K Sell
504
-624
-55% -$45K ﹤0.01% 221
2019
Q4
$88K Buy
1,128
+600
+114% +$46.9K ﹤0.01% 130
2019
Q3
$39K Buy
528
+66
+14% +$4.64K ﹤0.01% 156
2019
Q2
$28K Buy
462
+78
+20% +$4.72K ﹤0.01% 172
2019
Q1
$24K Hold
384
– – ﹤0.01% 190
2018
Q4
$20K Hold
384
– – ﹤0.01% 190
2018
Q3
$22K Buy
+384
New +$18.8K ﹤0.01% 131
2018
Q1
– Sell
-3,705
Closed -$139K – 215
2017
Q4
$139K Buy
3,705
+870
+31% +$31.9K 0.01% 160
2017
Q3
$103K Buy
2,835
+1,245
+78% +$47.5K 0.01% 182
2017
Q2
$63K Sell
1,590
-741
-32% -$27K 0.01% 216
2017
Q1
$73K Buy
2,331
+2,079
+825% +$65.1K 0.01% 191
2016
Q4
$8K Buy
252
+54
+27% +$1.75K ﹤0.01% 423
2016
Q3
$8K Hold
198
– – ﹤0.01% 377
2016
Q2
$7K Buy
+198
New +$6.77K ﹤0.01% 382

Other funds holding EW

Balentine LLC's EW Position: Q2 2024 in Review

Balentine LLC sold out of Edwards Lifesciences (EW) in Q2 2024, closing a stake of 11,770 shares — an estimated $1.12M sold.

Balentine LLC first reported a position in EW in Q2 2016 and held it in 24 quarters. The position peaked at $1.12M in Q1 2024. 1,297 funds tracked by Wall St. Rank hold EW as of Q2 2024.

  • Balentine LLC reported no remaining Edwards Lifesciences position as of Q2 2024 after selling out during the quarter.
  • Balentine LLC sold 11,770 Edwards Lifesciences shares in Q2 2024, an estimated $1.12M.
  • Balentine LLC first reported a position in Edwards Lifesciences in Q2 2016 and held it in 24 quarters.
  • Balentine LLC's Edwards Lifesciences position peaked at $1.12M in Q1 2024.
  • 1,297 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2024.

Based on Balentine LLC's 13F filing for Q2 2024, filed 7 Aug 2024.